Physician profile
Lisa A Flaherty
NPI 1386607315
$3,792.89
in general payments reported to CMS, 2019-2025
36 companies · $50.46 in 2025
The $50.46 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $504 · 2021: $492 · 2022: $910 · 2023: $1,025 · 2024: $161 · 2025: $50.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.45 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $873.82 | 2022-2025 | Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System, Navlock |
| Biogen, INC. | $336.16 | 2019-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $261.24 | 2019-2022 | |
| Amgen INC. | $210.53 | 2019-2023 | Aimovig |
| Life Spine, INC. | $187.50 | 2019 | |
| Abbvie INC. | $187.16 | 2021-2023 | |
| Emd Serono, INC. | $151.97 | 2019-2023 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $150.38 | 2019-2023 | |
| Genzyme Corporation | $137.04 | 2019-2022 | |
| Ucb, INC. | $134.26 | 2019-2023 | Nayzilam |
| Glaxosmithkline, LLC. | $124.55 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $122.30 | 2022 | |
| Allergan, INC. | $113.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $86.38 | 2021-2022 | |
| Csl Behring | $72.74 | 2022-2023 | Hizentra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $71.02 | 2020-2023 | |
| Acorda Therapeutics, INC | $65.00 | 2019-2020 | |
| Sk Life Science, INC. | $50.93 | 2021-2023 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $47.58 | 2021 | |
| Neurocrine Biosciences, INC. | $36.97 | 2022-2023 | Ongentys, Ingrezza |
| Ge Healthcare | $33.31 | 2019 | |
| Pfizer INC. | $31.68 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.99 | 2022 | |
| Medtronic Vascular, INC. | $30.69 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $28.18 | 2019-2020 | |
| Lilly USA, LLC | $25.68 | 2019-2020 | |
| Banner Life Sciences, LLC | $23.82 | 2023 | |
| Acadia Pharmaceuticals INC | $23.60 | 2023 | Nuplazid |
| Impel Pharmaceuticals INC. | $23.20 | 2022 | |
| Upsher-Smith Laboratories LLC | $20.96 | 2020 | |
| Adamas Pharmaceuticals, INC. | $20.88 | 2021 | |
| Neurelis, INC. | $17.81 | 2022 | |
| Viz.Ai, INC. | $16.79 | 2022 | |
| Genentech USA, INC. | $16.56 | 2019 | |
| Celgene Corporation | $16.21 | 2021 | |
| Fidia Pharma USA INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.